These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34667075)

  • 21. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy.
    Dovizio M; Veronesi C; Bartolini F; Cavaliere A; Grego S; Pagliaro R; Procacci C; Ubertazzo L; Bertizzolo L; Muzii B; Parisi S; Perrone V; Baraldi E; Bozzola E; Mosca F; Esposti LD
    Ital J Pediatr; 2024 Mar; 50(1):57. PubMed ID: 38528616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
    Ordóñez JE; Huertas VM
    BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada.
    Buchan SA; Chung H; To T; Daneman N; Guttmann A; Kwong JC; Murti M; Aryal G; Campigotto A; Chakraborty P; Gubbay J; Karnauchow T; Katz K; McGeer AJ; Dayre McNally J; Mubareka S; Richardson D; Richardson SE; Smieja M; Zahariadis G; Deeks SL
    J Pediatric Infect Dis Soc; 2023 Jul; 12(7):421-430. PubMed ID: 37335754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.
    Poshtiban A; Wick M; Bangert M; Damm O
    BMC Infect Dis; 2024 Aug; 24(1):844. PubMed ID: 39164625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
    Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
    J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
    Amand C; Tong S; Kieffer A; Kyaw MH
    BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
    Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
    Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory syncytial virus-associated hospitalizations over three consecutive seasons in children with congenital heart disease.
    Resch B; Kurath-Koller S; Hahn J; Raith W; Köstenberger M; Gamillscheg A
    Eur J Clin Microbiol Infect Dis; 2016 Jul; 35(7):1165-9. PubMed ID: 27126331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection.
    Chirikov VV; Simões EAF; Kuznik A; Kwon Y; Botteman M
    J Infect Dis; 2020 Mar; 221(8):1244-1255. PubMed ID: 30982895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study.
    Ares-Gómez S; Mallah N; Pardo-Seco J; Malvar-Pintos A; Pérez-Martínez O; Otero-Barrós MT; Súarez-Gaiche N; Santiago-Pérez MI; González-Pérez JM; López-Pérez LR; Rosón B; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F
    Pediatr Allergy Immunol; 2024 May; 35(5):e14131. PubMed ID: 38700124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.
    Wang X; Li Y; Shi T; Bont LJ; Chu HY; Zar HJ; Wahi-Singh B; Ma Y; Cong B; Sharland E; Riley RD; Deng J; Figueras-Aloy J; Heikkinen T; Jones MH; Liese JG; Markić J; Mejias A; Nunes MC; Resch B; Satav A; Yeo KT; Simões EAF; Nair H; ;
    Lancet; 2024 Mar; 403(10433):1241-1253. PubMed ID: 38367641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological study of hospitalization associated with respiratory syncytial virus infection in Taiwanese children between 2004 and 2007.
    Chi H; Chang IS; Tsai FY; Huang LM; Shao PL; Chiu NC; Chang LY; Huang FY
    J Formos Med Assoc; 2011 Jun; 110(6):388-96. PubMed ID: 21741007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA.
    Tran PT; Nduaguba SO; Wang Y; Diaby V; Finelli L; Choi Y; Winterstein AG
    Influenza Other Respir Viruses; 2024 Jul; 18(7):e13347. PubMed ID: 38951044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012.
    Reeves RM; Hardelid P; Gilbert R; Warburton F; Ellis J; Pebody RG
    Influenza Other Respir Viruses; 2017 Mar; 11(2):122-129. PubMed ID: 28058797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
    O'Shea TM; Sevick MA; Givner LB
    Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.